Valneva Announces Strong One-Year Phase 3 Results for IXCHIQ®, Its Single-Dose Chikungunya Vaccine in Adolescents

 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced additional positive Phase 3 results in adolescents for it...

January 21, 2025 | Tuesday | News
MediBeacon's TGFR System Receives FDA Approval for Kidney Function Assessment

MediBeacon Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the MediBeacon® TGFR for the assessment of kidney fu...

January 20, 2025 | Monday | News
Eli Lilly Secures FDA Approval for Omvoh® to Treat Moderately to Severely Active Crohn’s Disease

 Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for...

January 16, 2025 | Thursday | News
Kindeva and Emervax Forge Exclusive Partnership to Advance Next-Generation Vaccine Delivery Solutions

Kindeva Drug Delivery, a global CDMO and drug delivery expert, and Emervax, a developer of a proprietary circular RNA-based vaccine platform (e...

January 10, 2025 | Friday | News
FDA Accepts Revised sNDA for Astellas' IZERVAY™ in Treatment of Geographic Atrophy

 Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced the U.S. Food and Drug Administration (FDA) a...

January 09, 2025 | Thursday | News
Merck's GARDASIL® Becomes First HPV Vaccine Approved for Males in China

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the National Medical Products Administration (NMPA) of China approv...

January 09, 2025 | Thursday | News
Bio-Rad Launches Foresight™ Pro 45 cm Chromatography Columns for Biopharma Applications

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced the launch of Fores...

January 08, 2025 | Wednesday | News
VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Approved by Japan’s MHLW for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co-formulated wi...

December 31, 2024 | Tuesday | News
Takeda Receives Japanese Regulatory Approval for HYQVIA® in Primary and Secondary Immunodeficiency Disorders

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) announced that Takeda received regulatory approval for HYQVIA® [Immune Globulin Infusion 10%...

December 31, 2024 | Tuesday | News
FDA Approves First Generic of Victoza (Liraglutide) for Type 2 Diabetes, Expanding Access to Affordable Treatment

the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like pep...

December 24, 2024 | Tuesday | News
Keymed Biosciences’ Stapokibart (Kangyueda) Approved in China for Chronic Rhinosinusitis with Nasal Polyposis

Keymed Biosciences Inc. (HKEX: 02162) announced the National Medical Products Administration (the "NMPA") of China has recently approved the supp...

December 24, 2024 | Tuesday | News
Sanofi and SK bioscience Expand Collaboration to Develop Next-Generation Pneumococcal Vaccines for Global Impact

Sanofi and SK bioscience have entered into a new chapter of their collaboration in pneumococcal vaccines with an expanded agreement to develop, license and...

December 24, 2024 | Tuesday | News
Ultragenyx Doses First Patient in Pivotal Phase 3 Aspire Study for GTX-102 in Angelman Syndrome

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), announced that the first patient has been dosed in the pivotal Phase 3 Aspire study (NCT06617429) ...

December 20, 2024 | Friday | News
Valneva and Serum Institute of India Partner to Deliver Asia’s First Single-Shot Chikungunya Vaccine

  Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), the world’s...

December 19, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close